- 英文名称
- Istaroxime hydrochloride
- 分子式
- C21H33ClN2O3
- 分子量
- 396.95
- 中文别名
- (5S,8R,9S,10R,13S,14S,E)-3-((2-氨基乙氧基)亚氨基)-10,13-二甲基十四氢-1H-环戊烷并[a]菲-6,17-二酮盐酸盐; Istaroxime盐酸盐; 化合物 T15599; (5S,8R,9S,10R,13S,14S)-3-((2-Aminoethoxy)imino)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthrene-6,17-dione hydrochloride; (5S,8R,9S,10R,13S,14S)-3-(2-aminoethoxyimino)-10,13-dimethyl-1,2,4,5,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-6,17-dione,hydrochloride; Androstane-3,6,17-trione,3-(O-(2-aminoethyl)oxime),hydrochloride (1:1); Androstane-3,6,17-trione,3-(O-(2-aminoethyl)oxime),monohydrochloride,(5alpha); PST-2744 hydrochloride; Istaroxime (hydrochloride); PST2744 (hydrochloride); PST 2744 (hydrochloride); (5alpha)-Androstane-3,6,17-trione 3-[O-(2-aminoethyl)oxime] monohydrochloride; PST2774; PST-2774
- 用途
- 作为Na+/K+-ATPase抑制剂(IC50=0.11μM)和肌浆/内质网钙ATP酶2(SERCA 2)激活剂;通过抑制Na+/K+-ATPase发挥正性肌力作用;体外研究显示其抑制狗肾Na+/K+-ATPase活性的IC50为0.43±0.15μM,抑制豚鼠肾Na+/K+-ATPase活性的IC50为8.5μM;体内研究显示其在累积剂量1.89±0.37mg/kg时+dP/dt max达80%(ED80),在4.88±0.6mg/kg时达峰值140±3.5%(EDmax)